New test for CML mutations in patients switching TKI
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a new, highly sensitive blood test (digital PCR) to find BCR::ABL1 mutations in people with chronic-phase CML who are switching their tyrosine kinase inhibitor (TKI) because of resistance or a warning sign. The goal is to see if this test can help guide treatment decisions more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your CML diagnosis must be confirmed by a BCR::ABL1 genetic test
- You have the e13a2 or e14a2 type of the BCR::ABL1 gene
- You are 18 years or older
- Your CML must be in the chronic phase (not advanced)
- You are currently taking imatinib, dasatinib, nilotinib, or bosutinib
- You are switching TKI because your current drug isn't working well (resistance) or there is a 'warning' response
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
This trial looks at how well children with chronic myeloid leukemia (CML) respond to standard “TKI” tablets when treatment starts. It uses genetic test results from diagnosis (DNA/RNA) to understand which children respond better and why.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.